
Human Prostate-specific antigen 165-174, FLTPKKLQCV
Description
About Human Prostate-specific antigen 165-174, FLTPKKLQCV
The Human Prostate-specific antigen Peptide (IEDB: 1637461) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Prostate-specific antigen Peptide, H-FLTPKKLQCV-OH (Uniprot: P07288 aa: 165-174) from JPT is produced under strict quality control and quality management.
Human Prostate-specific antigen 165-174, FLTPKKLQCV - Specifications
- Peptide sequence: H-FLTPKKLQCV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Adenocarcinoma, Prostate cancer, Breast cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Prostate-specific antigen 165-174, FLTPKKLQCV
References:
Read References with JPT’s Antigen Peptides
Human Prostate-specific antigen 165-174, FLTPKKLQCV has been described in:
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide., J Immunol, 1998 (PMID: 9743387)
Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer., Urology, 1998 (PMID: 9457311)
Documentation
Documentation for Human Prostate-specific antigen 165-174, FLTPKKLQCV
Properties
Properties of Human Prostate-specific antigen 165-174, FLTPKKLQCV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Adenocarcinoma, Breast cancer, Prostate cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Prostate-specific antigen 165-174, FLTPKKLQCV
Information | Values |
---|---|
Sequence: | H-FLTPKKLQCV-OH |
Specifications: | 10mer peptide as TFA salt |